# Insights and Reporting

This section presents the cost, utilization, population, and chronic-condition findings from the CMS Medicare DE-SynPUF project and connects them to healthcare payer business questions.

---

## Purpose

The purpose of this analysis is to identify where claim payments and utilization are concentrated, explain differences across beneficiary groups, and define the next analyses needed to support business decisions.

The report distinguishes between:

* Findings supported by the existing descriptive analysis.
* Interpretations of those findings.
* Proposed additional analyses.
* Potential business actions that require further evidence.
* Measures that could be used to evaluate those actions.

No intervention outcomes or cost savings have been demonstrated.

---

## What This Section Includes

* Executive summary
* Cost concentration
* Utilization concentration
* Population and geographic variation
* Age
* Chronic condition burden
* High-intensity conditions
* Multimorbidity and risk stratification
* Cross-cutting business recommendations
* Analytical limitations
* GitHub portfolio structure
* Current analysis status

---

## Executive Summary

The analysis examines inpatient and outpatient claim payments and utilization using CMS Medicare DE-SynPUF data from 2008–2010.

The main business question is:

**Which care settings and beneficiary populations account for the greatest spending and utilization, and what should a payer investigate before selecting an intervention?**

Key findings include:

* Inpatient claims represented **7.88% of claim volume but 75.26% of total payments**.
* The top **10% of beneficiaries by claim volume accounted for 28.85% of all claims**.
* States with the highest total spending were not necessarily those with the highest spending per beneficiary-year.
* Beneficiaries aged **85 and older** had greater spending and utilization per beneficiary-year than beneficiaries aged **65–74**.
* Highly prevalent conditions created substantial population burden, while some less prevalent condition groups had higher spending per beneficiary.
* Higher chronic-condition counts were associated with increasing claim frequency and spending intensity.

These patterns support further profiling and segmentation. They do not establish that expensive care is avoidable or that frequent utilization is inappropriate.

**Measurement note:** Cost refers to claim payment amounts in the included inpatient and outpatient files. A beneficiary-year represents one beneficiary observed in one year and does not necessarily represent a full year of enrollment.

---

## Cost Concentration

### Finding

| Care Setting | Claims | Share of Claims | Total Payments | Share of Payments |
|---|---|---|---|---|
| Inpatient | 66,637 | 7.88% | $636,770,480 | 75.26% |
| Outpatient | 779,533 | 92.12% | $209,292,350 | 24.74% |

Claims in the **$10,000–$50,000** range accounted for approximately **42% of total claim costs ($362.7M)** while representing about **2% of claim volume**.

The original findings also reported that the **top 10% of claims accounted for approximately 51% of total costs**.

**Validation note:** The 51% figure is preserved as reported, but the saved SQL ranks beneficiaries by total payments rather than individual claims. The unit must be reconciled before presenting this as a claim-level finding.

Under a consistent claim universe with nonnegative payments, the highest-cost 10% of claims could not account for less spending than an inpatient subset representing 7.88% of claims and 75.26% of payments.

The cost-band calculation also requires a rounding check: $362.7M divided by the combined reported payments is approximately 42.87%.

### Interpretation

Inpatient care accounts for most included payments despite representing a small share of claims.

The setting, cost-band, and concentration results should support one coordinated investigation of high-cost spending.

### Business Question

Which care settings, episode types, and beneficiary characteristics explain the concentration of high-cost spending?

### Recommended Next Analysis

* Reconcile the concentration unit, ranking logic, cost-band boundaries, and rounding.
* Compare high-cost claims with other claims by setting and diagnosis group.
* Examine payment distributions and length of stay where available.
* Separate isolated expensive episodes from repeated hospital use.

### Potential Business Action

If a specific episode type explains high spending, prepare a focused review for clinical and payment specialists.

If repeated hospital episodes explain the concentration, evaluate whether the affected subgroup has transition or coordination needs.

High payment amounts alone do not establish preventability or inappropriate billing.

### KPIs and How to Measure

| KPI | Measurement |
|---|---|
| Payment concentration | Segment payments divided by total included payments |
| Claim payment intensity | Median and upper-percentile payment per claim |
| Inpatient payment share | Inpatient payments divided by total included payments |
| Repeated inpatient use | Defined inpatient episodes per beneficiary |

Establish validated baselines before setting improvement targets.

---

## Utilization Concentration

### Finding

The **top 10% of beneficiaries by claim volume accounted for 28.85% of all claims**.

### Interpretation

A relatively small beneficiary group accounts for a substantial share of claim activity.

However, high claim frequency does not necessarily indicate high spending, unnecessary services, or poor coordination. Claims are billing records and are not automatically equivalent to visits or admissions.

### Business Question

Are high-utilization beneficiaries also high-cost beneficiaries, and what explains the differences between these groups?

### Recommended Next Analysis

Aggregate payments and claim counts to the same beneficiary and observation period. Define separate high-cost and high-utilization groups, document ranking and tie handling, and compare four segments.

| Proposed Segment | Main Analytical Focus |
|---|---|
| Higher utilization and higher cost | Complex illness, repeated hospital use, and coordination needs |
| Higher utilization and lower cost | Routine monitoring, frequent outpatient activity, and possible fragmentation |
| Lower utilization and higher cost | A small number of expensive episodes |
| Lower utilization and lower cost | Observed need, access, and completeness of follow-up |

Assess whether high utilization persists across years.

### Potential Business Action

Use the identified pattern to select the review pathway.

Persistent frequent hospital users with demonstrated coordination needs could be evaluated for case management. Beneficiaries with isolated expensive episodes could receive an episode-specific review.

Lower recorded utilization should not automatically be labeled low clinical risk.

### KPIs and How to Measure

* **High-cost overlap:** Beneficiaries in both groups divided by high-utilization beneficiaries.
* **Utilization intensity:** Claims per beneficiary-year.
* **Persistence:** Percentage remaining in the high-utilization group the following year.
* **Hospital use:** Defined inpatient episodes per beneficiary-year.

A future program should measure appropriate care and coordination outcomes, rather than treating every reduction in claims as success.

---

## Population and Geographic Variation

### Finding

California generated the highest total spending at approximately **$67.1M** and represented **8.79% of beneficiary-years**, the largest population share.

Several other states had higher spending per beneficiary-year.

| State | Cost per Beneficiary-Year |
|---|---:|
| Indiana | $2,948 |
| Maryland | $2,943 |
| New Jersey | $2,943 |
| Kentucky | $2,927 |
| Nebraska | $2,916 |

### Interpretation

Total spending reflects population size as well as spending intensity.

Dividing by beneficiary-years adjusts for the number of observed beneficiary-year records. It does not adjust for clinical risk, enrollment duration, or payment differences.

These geographic differences do not establish inefficiency.

### Business Question

Do higher state averages reflect more claims, more expensive claims, a greater inpatient share, or different beneficiary characteristics?

### Recommended Next Analysis

Decompose spending using:

**Cost per beneficiary-year = Claims per beneficiary-year × Cost per claim**

Compare states within consistent age, year, and chronic-condition groups. Display population sizes and assess whether differences persist after standardizing population composition where feasible.

### Potential Business Action

A payer planning team could distinguish markets requiring greater overall capacity because of population size from markets requiring investigation of elevated utilization or episode intensity.

Synthetic state rankings should be treated as an analytical demonstration, not real-market investment guidance.

### KPIs and How to Measure

Track the following by state:

* Cost per beneficiary-year.
* Claims per beneficiary-year.
* Payment per claim.
* Inpatient payment share.
* Beneficiary-year counts.

Compare standardized differences against a documented reference population and flag small groups.

---

## Age

### Finding

The **65–74 age group** generated approximately **$275.5M** in total spending and represented **39.55% of beneficiary-years**, the largest population share.

Beneficiaries aged **85 and older** had the highest reported spending and claim frequency per beneficiary-year.

| Age Group | Cost per Beneficiary-Year | Claims per Beneficiary-Year |
|---|---:|---:|
| 65–74 | Approximately $2,027 | 2.16 |
| 85 and older | Approximately $3,051 | 2.81 |

### Interpretation

The 65–74 group carries a large aggregate spending burden because of its size, while the oldest group has greater average spending intensity.

The analysis does not isolate an independent effect of age from multimorbidity, enrollment duration, or other characteristics.

### Business Question

How much of the higher spending among beneficiaries aged 85 and older is associated with chronic-condition burden and inpatient use?

### Recommended Next Analysis

* Compare age groups within condition-count strata.
* Examine inpatient payment share and repeated episodes.
* Review observation time and partial-year enrollment.
* Document how age is assigned for each year.

### Potential Business Action

If repeated hospital use and transition needs explain elevated spending in an older subgroup, evaluate discharge follow-up and coordination support for that subgroup.

Eligibility should reflect demonstrated needs and clinical review rather than age alone.

### KPIs and How to Measure

Track cost and claims per beneficiary-year within age and condition strata, inpatient episodes per 1,000 beneficiary-years, and cohort size.

A future transition program could measure timely follow-up and repeat admissions using documented eligibility and follow-up rules.

---

## Chronic Condition Burden

### Finding

| Condition | Beneficiary Prevalence |
|---|---:|
| Ischemic heart disease (IHD) | 63.35% |
| Diabetes | 55.20% |
| Congestive heart failure (CHF) | 51.09% |
| Depression | 40.90% |
| Alzheimer’s disease | 39.67% |
| Osteoporosis | 36.56% |
| Chronic kidney disease (CKD) | 32.43% |

Beneficiaries with IHD were associated with **610,013 claims**, representing **72.09% of all claims**.

Diabetes and CHF were associated with **560,274** and **466,335 claims**, respectively.

### Interpretation

Common cardiovascular and metabolic conditions create substantial population burden.

These claims are associated with beneficiaries who have a condition; they are not necessarily caused exclusively by that condition.

Beneficiaries can appear in multiple condition groups. Condition-associated claims and payments therefore overlap and should not be summed as independent totals.

The saved prevalence query identifies unique beneficiaries flagged in any observed year. It measures period prevalence, assuming correctly coded condition indicators.

### Business Question

Which common condition combinations create the largest population for a clearly defined population-health service?

### Recommended Next Analysis

* Create annual and period prevalence measures with explicit denominators.
* Examine overlap among IHD, diabetes, and CHF.
* Compare mutually exclusive condition combinations.
* Assess care gaps only when suitable service, enrollment, or clinical data are available.

### Potential Business Action

Use prevalence to estimate potential outreach scale, then narrow eligibility to a demonstrated care need.

Deduplicate beneficiaries across programs so people with multiple conditions do not receive disconnected outreach from several teams.

### KPIs and How to Measure

| KPI | Measurement |
|---|---|
| Condition prevalence | Unique beneficiaries with the condition divided by the relevant population |
| Condition overlap | Beneficiaries with multiple selected conditions |
| Program reach | Eligible beneficiaries successfully reached divided by all eligible beneficiaries |
| Follow-up completion | Completed indicated follow-up divided by beneficiaries requiring it |

Outreach and follow-up measures require additional operational data and are not current findings.

---

## High-Intensity Conditions

### Finding

| Condition Group | Claims per Beneficiary | Approximate Cost per Beneficiary |
|---|---:|---:|
| TIA | 5.52 | $10,086 |
| End-stage renal disease (ESRD) | 5.52 | $8,706 |
| Chronic kidney disease (CKD) | 5.45 | $8,633 |
| Chronic obstructive pulmonary disease (COPD) | 5.53 | $8,445 |

For comparison, IHD averaged **4.19 claims per beneficiary**.

TIA is retained as the project’s condition label. Its underlying coding definition should be documented before clinical interpretation.

### Interpretation

The most prevalent conditions are not necessarily those with the highest spending per beneficiary.

These payments include care associated with coexisting illnesses. They do not isolate the incremental cost caused by one condition.

**Denominator qualification:** The saved condition query divides claims from condition-positive beneficiary-years by unique beneficiaries ever flagged during the study period. These values are not annual beneficiary-year rates.

### Business Question

Within each condition group, is elevated spending associated with frequent services, inpatient episodes, or coexisting conditions?

### Recommended Next Analysis

Create an annual view using aligned condition-positive beneficiary-years and claims.

Examine setting mix, repeated hospital use, and spending within comparable age and condition-count groups. Review CKD and ESRD overlap before treating them as separate target populations.

### Potential Business Action

Develop condition-specific review pathways when the analysis identifies a concrete need.

Recurrent inpatient use in a COPD subgroup and fragmented services in a renal subgroup would require different investigations. Select a pilot only after defining its care process, eligible population, and clinical rationale.

### KPIs and How to Measure

Track:

* Annual cost per beneficiary-year.
* Inpatient payment share.
* Repeated inpatient episodes.
* Eligible population size.
* Pathway completion if a program is implemented.

Account for beneficiaries appearing in multiple condition groups.

---

## Multimorbidity and Risk Stratification

### Finding

Utilization and spending increased consistently as chronic-condition counts increased.

| Chronic-Condition Count | Claims per Beneficiary-Year | Approximate Cost per Beneficiary-Year |
|---|---:|---:|
| 0 | 2.13 | $740 |
| 6 | 5.94 | $7,392 |
| 10 | 9.56 | $21,537 |
| 12 | 11.51 | $38,511 |

Cost per claim increased from approximately **$347** among beneficiaries with no conditions to more than **$3,345** among those with 12 conditions.

The original output included only **338 beneficiary-years with 11 conditions** and **43 with 12 conditions**.

### Interpretation

Greater condition burden is associated with both more claims and higher payments per claim.

Condition count is a candidate segmentation variable, but the relationship is not a validated prediction model.

The query uses an inner join, excluding beneficiary-years without matched claims. Its rates therefore describe claim-active beneficiary-years.

### Business Question

Can condition burden and prior utilization identify a manageable population for further clinical review?

### Recommended Next Analysis

Evaluate exploratory groups of:

* **0–2 conditions**
* **3–5 conditions**
* **6 or more conditions**

These thresholds are proposed, not optimized or clinically validated.

Compare population counts, payment shares, inpatient use, and condition combinations. Create an all-beneficiary-year view with appropriate zero-claim treatment.

Where possible, assess later-year outcomes using information available in an earlier year.

### Potential Business Action

Evaluate a screening rule combining higher condition burden with persistent utilization.

Route qualifying beneficiaries to clinical review before determining whether case management is appropriate. Choose thresholds according to demonstrated need, review capacity, and later-year performance.

### KPIs and How to Measure

Track beneficiary-year counts, claims, payment shares, and inpatient episode rates by stratum.

For a proposed screening rule, measure:

* Future high-cost beneficiaries identified.
* Clinical review yield.
* Eligible caseload.
* Performance in a later observation period.

Emphasize the 0, 6, and 10 condition comparisons rather than relying on the small 12-condition group.

---

## Cross-Cutting Business Recommendations

### Establish Consistent Measurement

Reconcile the approximately 51% concentration result, cost-band rounding, and denominator definitions before using them in headline presentations.

Create a metric dictionary specifying:

* Unit of analysis and observation period.
* Population and claim inclusion criteria.
* Numerator and denominator.
* Condition definitions.
* Zero-claim and partial-year treatment.

Every headline metric should map to a documented query and output.

### Combine Cost and Utilization Profiling

Use claim-level financial analysis alongside beneficiary-level utilization analysis.

Distinguish expensive individual episodes from persistent frequent use, then route each pattern to the appropriate review team.

Measure whether flagged cases reveal a specific reviewable issue. The number of cases flagged is not evidence that an intervention is needed.

### Separate Population Reach from Individual Intensity

Use prevalence and condition overlap to estimate the scale of broad population-health activities.

Use annual intensity, repeated episodes, and clinical needs to evaluate smaller populations for more intensive support.

Geography and age should inform capacity and subgroup comparisons after accounting for population differences.

### Evaluate a Defined Pilot Before Expansion

For a future operational application, specify:

* Target population.
* Qualifying event or eligibility rule.
* Service offered.
* Accountable team.
* Follow-up period.
* Outcome measures.

Compare outcomes with a suitable comparison group and account for baseline differences and regression to the mean.

Measure program delivery, access, quality, and payments together. Include program costs when evaluating net financial benefit.

No improvement target or savings estimate is established by the current analysis.

---

## Limitations

* **Synthetic and historical data:** Results demonstrate analytical methods and should not be presented as current Medicare benchmarks or real state performance.
* **Limited payment scope:** Included inpatient and outpatient payments do not represent all healthcare spending, patient liability, or provider costs.
* **Descriptive relationships:** Findings do not establish causality, preventability, fraud, waste, or intervention effectiveness.
* **Concentration validation:** The approximately 51% result requires reconciliation because the narrative refers to claims while the saved SQL ranks beneficiaries.
* **Rounding:** The approximately 42% cost-band result requires consistent boundaries, denominator selection, and rounding.
* **Different denominators:** Unique beneficiaries, beneficiary-years, and condition-positive beneficiary-years are not interchangeable.
* **Claim-active cohort:** The multimorbidity query excludes beneficiary-years without claims.
* **Overlapping conditions:** Condition-associated claim and payment totals can overlap and should not be summed.
* **Small groups:** Extreme multimorbidity categories have limited observations.
* **Exposure and follow-up:** A beneficiary-year record does not guarantee full-year enrollment or sufficient follow-up.
* **Evidence status:** Reported findings are preserved. This report is not a complete independent rerun of every result, and no intervention outcomes or savings are claimed.

---

## GitHub Portfolio Structure

This report belongs in the existing **Insights and reporting** folder.

```text
Insights and reporting/
└── medicare-analysis.md
```

The repository sections support different parts of the analytical workflow:

| Repository Section | Role in the Portfolio |
|---|---|
| Data Profiling | Initial dataset structure and quality assessment |
| Data/Raw Data | Dataset information and source organization |
| Documentation | Project methodology and supporting documentation |
| Images | Visual assets used in project documentation |
| Insights and reporting | Findings, business interpretations, recommendations, and limitations |
| Power BI Dashboard | Dashboard documentation and completed visualizations |
| SQL Data Base | Database and SQL analysis documentation |
| README.md | Project overview and navigation to detailed work |

The main README should summarize the business problem, scope, tools, and validated findings, then link to this report.

Document dataset selection, transformations, query order, and metric definitions so reviewers can trace the reported results.

---

## Status

Descriptive findings have been organized into business themes.

Recommended next analyses, potential business actions, and measurement approaches have been documented.

The concentration metric, cost-band rounding, and denominator definitions require reconciliation before being used as headline results.

Risk segmentation and intervention evaluation remain proposed next steps. No program outcomes or financial savings have been demonstrated.
